Douglas E. Paull, MD, MS and Paul N. Uhlig, MD, MPA
Risk managers can help patient-subjects and clinician-researchers make informed novel device implantation decisions in the absence of preclinical trial data.
AMA J Ethics. 2020;22(11):E911-918. doi:
10.1001/amajethics.2020.911.
The authors of a recent journal article believe that most doctors and clinical trial sponsors would not object to changes in regulations requiring doctors to disclose financial incentives to their patients.
A case that explores the impact of financial incentives from insurance companies on the patient-physician relationship and whether or not they should be disclosed to a patient.
When patients and physicians disagree on the use of genetic engineering technology, physicians must act in accordance with professional ethics and society's guidelines.
Adrienne W. Henize, JD and Andrew F. Beck, MD, MPH
Data on certain chronic conditions’ prevalence, incidence of potentially preventable morbidity, and health-harming legal factors influence approaches to care.
AMA J Ethics. 2024;26(8):E648-654. doi:
10.1001/amajethics.2024.648.
Professor Adrienne W. Henize joins Ethics Talk to discuss her article, coauthored with Dr Andrew F. Beck: “What Are Epidemiological Foundations for Integrating Legal Services Into Health Care Settings?”